









Markets
/
Stocks
/
nasdaq-celc
/

Celcuity Inc

CELC

106.750USD

+2.470+2.37%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.62BMarket Cap

LossP/E TTM



Celcuity Inc

106.750

+2.470+2.37%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Celcuity Inc

Currency: USD Updated: 2026-02-06

Key Insights

Celcuity Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 111 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 110.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Celcuity Inc's Score

Industry at a Glance

Industry Ranking

111 / 392

Overall Ranking

241 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Celcuity Inc Highlights

StrengthsRisks

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -28.95, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.79M shares, increasing 0.74% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 194.80K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.73.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

110.500

Target Price

+5.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Celcuity Inc is 6.30, ranking 270 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.30

Change



Financials

6.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.53

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Celcuity Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Celcuity Inc is 6.87, ranking 208 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -28.95, which is -90.70% below the recent high of -2.69 and -9.84% above the recent low of -31.80.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 111/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Celcuity Inc is 8.73, ranking 66 out of 392 in the Biotechnology & Medical Research industry. The average price target is 108.00, with a high of 134.00 and a low of 94.00.

Score

Industry at a Glance

Previous score

8.73

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

110.500

Target Price

+5.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Celcuity Inc

CELC

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Celcuity Inc is 7.27, ranking 84 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 117.92 and the support level at 97.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.05

Change

0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-2.117

Neutral

RSI(14)

49.216

Neutral

STOCH(KDJ)(9,3,3)

18.454

Sell

ATR(14)

6.071

High Vlolatility

CCI(14)

-76.922

Neutral

Williams %R

78.342

Sell

TRIX(12,20)

0.279

Sell

StochRSI(14)

35.766

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

108.192

Sell

MA10

110.829

Sell

MA20

109.231

Sell

MA50

104.840

Buy

MA100

85.465

Buy

MA200

55.320

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Celcuity Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 87.00%, representing a quarter-over-quarter decrease of 11.92%. The largest institutional shareholder is The Vanguard, holding a total of 2.28M shares, representing 4.92% of shares outstanding, with 11.39% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

7.92M

+2.20%

Sullivan (Brian F)

3.12M

+3.18%

Perceptive Advisors LLC

2.96M

+10.70%

New Enterprise Associates (NEA)

2.14M

The Vanguard Group, Inc.

Star Investors

2.06M

+23.46%

BlackRock Institutional Trust Company, N.A.

2.04M

+9.35%

Morgan Stanley & Co. LLC

1.27M

+142.39%

Laing (Lance G Ph.D.)

1.25M

Soleus Capital Management, L.P.

1.18M

-60.86%

Tang Capital Management, LLC

1.15M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Celcuity Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.